Drug after chemo-embolization for liver cancer that can’t be removed
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 study tests PTX-9908 (a study drug) to see if it’s safe and effective when given after TACE, a liver-directed treatment. It may help people with liver cancer that can’t be surgically removed and who have recovered enough from their recent TACE.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that can’t be surgically removed and is either intermediate-stage or fits Child-Pugh A/B with large or multiple tumors, with no major blood vessel invasion.
- You finished TACE within the past 4 weeks, and your key liver blood tests (ALT/AST and bilirubin) are back to normal or to your pre-TACE baseline.
- Your overall health is good enough, with an ECOG score under 2.
- Your blood counts and organs are strong enough: low white blood cells, anemia, or low platelets are not allowed; kidney function (eGFR) must be above 60.
- You must not have pregnancy, and you must agree to effective birth control during the study and for at least 4 weeks after.
- Your heart rhythm tests must be acceptable (no significant QT/QTc prolongation), and you should not take medicines that can prolong QT/QTc.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
Hear when a new Carcinoma, Hepatocellular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.